Costs will be estimated from these charges using a hospital-specific departmental ratio of costs to charges. The accuracy of these cost estimates will be assessed by comparing them with estimates derived from the application of the chart-based formula for calculating imputed charges developed by Kukall et al. 67 The effects of all varying clinical and cost estimates will be examined using sensitivity analysis.
Conclusion
The results of these studies demonstrate that a number of factors contribute to the costs and cost-effectiveness of agents used to treat malignant pleural effusion. The largest proportion of the cost of pleurodesis appears to be attributable to the performance of the sclerosing agent, including complete response rate, number of administra¬ tions necessary to achieve complete response, and the relapse rate. These factors affect the length of hospital stay, personnel costs, diagnostic costs, and the risk of adverse effects. These properties make doxycycline and the interferons costly choices for treatment, despite high initial response rates and low frequencies of adverse effects. The second major contributor to cost-effectiveness appears to be procedural costs. The highly sophisticated procedures required to administer talc make it one of the more costly treatments, despite its low cost and strong efficacy. Efficacy and adverse effect profiles have to be considered when cost-effectiveness issues are analyzed. The flow diagram shown in Figure 1 can help physicians make decisions regarding the optimal treatment of pa¬ tients with malignant pleural effusions. Future compari¬ sons of the ambulatory approach with the traditional approach, requiring hospitalization to drain malignant pleural effusions followed by sclerosis, will allow therapy to be defined based not only on efficacy, but also on the use.and expense.of related resources.
